组蛋白去乙酰化酶6在弥漫性大B细胞淋巴瘤中的表达及意义

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (2634 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：观察组蛋白去乙酰化酶6（HDAC6）在弥漫性大B细胞淋巴瘤（DLBCL）中的表达情况，并探讨其与各种临床病理因素及生存情况的关系。方法：选取2007年12月-2015年9月在温州医科大学附属第二医院确诊的93例DLBCL患者和15例反应性淋巴结增生患者作为研究对象。应用免疫组织化学染色检测DLBCL组织HDAC6蛋白表达情况，χ2检验和Kaplan-Meier法分析HDAC6的表达与各种临床因素和生存情况的关系。结果：在93例DLBCL组织中HDAC6高表达率为69.9%，显著高于反应性淋巴结增生组织的20%（P＜0.05）。在DLBCL中，高表达组国际预后指数（IPI）评分为0～2分的比例显著高于低表达组（P＜0.05），乳酸脱氢酶升高和β2-微球蛋白值升高比例均显著低于低表达组（P＜0.05）。Kaplan-Meier生存分析结果显示HDAC6高表达组的5年总生存时间和无进展生存时间均显著高于低表达组。结论：HDAC6在DLBCL患者中呈高表达，高表达组患者有IPI评分低和肿瘤负荷轻的特点。HDAC6高表达是DLBCL的良好预后因素。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	林晓骥
	钱紫君
	倪励斌
	孙妮
	周晓海
	童欢欢
	周舒萍
	姚荣欣

关键词 ： , 弥漫性大B细胞淋巴瘤；组蛋白去乙酰化酶6；预后

Abstract：Objective: To explore the histone deacetylase 6 (HDAC6) expression in diffuse large B-cell lymphoma (DLBCL) and to analyze its relationship with the clinicopathological characteristics and survival. Methods: The clinical data from 93 DLBCL patients and 15 patients with reactive hyperplasia of lymph node who were treated in the Second Affiliated Hospital of Wenzhou Medical University from December 2007 to September 2015 was retrospectively analyzed. Cases were subjected to immunohistochemical staining for HDAC6 protein expression in the DLBCL tissue. SPSS was used to analyze the relationship between HDAC6 expression and various clinical factors, and the relationship between HDAC6 and survival. Results: High expression rates of HDAC6 protein in 93 DLBCL tissues were 69.9%, which was significantly higher than 20% in reactive hyperplasia of lymph node (P<0.05). In DLBLC, the ratio of IPI (0-2) in high expression group was significantly higher than that in low expression group but the ratio of increased LDH and β2-microglobulin in high expression group was significantly lower than that in low expression group (P<0.05). On Kaplan-Meier analysis, the 5-year overall survival and the 5-year progression free survival in high expression group was significantly higher than that in the low expression one. Conclusion: HDAC6 is highly expressed in DLBCL patients, patients with highly expressed HDAC6 represents low IPI score and light tumor burden. The highly expressed HDAC6 as a favorable prognostic factor has more prognostic value for DLBCL.

Key words： diffuse large B-cell lymphoma histone deacetylase 6 prognosis

收稿日期: 2016-07-01

基金资助:温州市科技局科研基金资助项目（Y20130205）。

通讯作者: 姚荣欣，主任医师，硕士生导师，Email：yaorx0821@ 163.com

作者简介: 林晓骥（1983-），男，浙江温州人，主治医师

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2017/V47/I6/421

[1] ARMITAGE J O, WEISENBURGER D D. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project[J]. J Clin Oncol, 1998, 16(8): 2780-2795.
[2] GASCOYNE R D. Emerging prognostic factors in diffuse large B cell lymphoma[J]. Curr Opin Oncol, 2004, 16(5):436-441.
[3] 赵静, 黄小芳, 杨开颜, 等. ZAP-70在B细胞非霍奇金淋巴瘤中的表达及其意义[J]. 温州医学院学报, 2009, 39(6): 616-618.
[4] MARQUARD L, GJERDRUM L M, CHRISTENSEN I J, et al. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutane-ous T-cell lymphoma[J]. Histopathology, 2008, 53(3): 267-277.
[5] SABATTINI E, BACCI F, SAGRAMOSO C, et a1. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview[J]. Pathologica, 2010, 102(3): 83-87.
[6] ROSENBERG S A. Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas[J]. Cancer Treat Rep, 1977, 61(6): 1023-1027.
[7] CHESON B D, HORNING S J, COIFFIER B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas[J]. J Clin Oncol, 1999, 17(4): 1244.
[8] ZHANG Z, YAMASHITA H, TOYAMA T, et al. HDAC6 expression is correlated with better survival in breast cancer[J]. Clin Cancer Res, 2004, 10(20): 6962-6968.
[9] LEE Y S, LIM K H, GUO X, et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis[J]. Cancer Res, 2008, 68(18): 7561-7569.
[10] AZUMA K, URANO T, HORIE-INOUE K, et al. Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells [J]. Cancer Res, 2009, 69(7): 2935-2940.
[11] KAKIHANA M, OHIRA T, CHAN D, et al. Induction of Ecadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition[J]. J Thorac Oncol, 2009, 4(12): 1455-1465.
[12] HIDESHIMA T, BRADNER J E, WONG J, et al. Small molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma [J]. Proc Natl Acad Sci U S A, 2005, 102(24): 8567-8572.
[13] SAKUMA T, UZAWA K, ONDA T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma[J]. Int J Oncol, 2006, 29(1): 117-124.
[14] MARQUARD L, POULSEN C B, GJERDRUM L M, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B-and T-cell lymphomas[J]. Histopathology, 2009, 54(6): 688-698.